Cowen and Company reiterated their hold rating on shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in a research report sent to investors on Monday. The firm currently has a $25.00 price target on the stock.

A number of other equities analysts have also weighed in on MYGN. Jefferies Group LLC reiterated a hold rating and issued a $21.00 price target (up previously from $18.00) on shares of Myriad Genetics in a research report on Wednesday, May 3rd. Deutsche Bank AG raised their price objective on Myriad Genetics from $15.00 to $20.00 and gave the stock a sell rating in a research report on Monday, May 8th. BidaskClub upgraded Myriad Genetics from a sell rating to a hold rating in a research report on Friday, June 9th. J P Morgan Chase & Co restated an underweight rating and set a $16.00 price objective on shares of Myriad Genetics in a research report on Friday, June 30th. Finally, Piper Jaffray Companies restated a hold rating and set a $22.00 price objective on shares of Myriad Genetics in a research report on Friday, July 14th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. Myriad Genetics presently has an average rating of Hold and an average target price of $21.78.

Myriad Genetics (NASDAQ:MYGN) traded up 1.04% on Monday, reaching $28.16. 434,738 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $25.23 and its 200 day moving average is $21.08. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $28.39. The stock has a market capitalization of $1.93 billion, a P/E ratio of 88.28 and a beta of 0.31.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business had revenue of $200.50 million during the quarter, compared to analyst estimates of $193.71 million. During the same quarter last year, the company posted $0.36 EPS. Myriad Genetics’s revenue for the quarter was up 7.5% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.04 EPS for the current year.

WARNING: “Myriad Genetics’ (MYGN) Hold Rating Reiterated at Cowen and Company” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/15/myriad-genetics-mygn-hold-rating-reiterated-at-cowen-and-company.html.

Several large investors have recently bought and sold shares of the company. Norges Bank purchased a new stake in Myriad Genetics during the fourth quarter worth $14,319,000. Arizona State Retirement System purchased a new stake in Myriad Genetics during the first quarter worth $682,000. Bank of New York Mellon Corp increased its stake in Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after buying an additional 521,146 shares during the period. Frontier Capital Management Co. LLC increased its stake in Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock worth $59,058,000 after buying an additional 41,432 shares during the period. Finally, Great West Life Assurance Co. Can increased its stake in Myriad Genetics by 958.4% in the first quarter. Great West Life Assurance Co. Can now owns 97,514 shares of the company’s stock worth $1,870,000 after buying an additional 88,301 shares during the period.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.